Glycorex Transplantation AB (publ): Interim Report January – March 2023
January – March 2023 · Net sales: SEK 7.0 million (6.8) · Operating income: SEK -4.3 million (-4.0) · Net income for the period: SEK -4.3 million (-4.1) · Earnings per share: SEK -0.06 (-0.06) Summary of the quarter · 3% sales growth. · The first study on whole blood is published showing that Glycosorb® ABO effectively reduces anti-A/B antibodies without increased haemolysis (destruction of red blood cells). · The first blood group incompatible kidney transplant with Glycosorb® ABO in South Africa is performed. · Great Ormond Street Hospital in England